Raleigh Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Raleigh Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11	Closed	-$2.2K	–	689
2026 Q1	$2.2K	Buy	+11	New	+$2.18K	﹤0.01%	512
2025 Q1	–	Sell	-25	Closed	-$2.68K	–	830
2024 Q4	$2.68K	Hold	25	–	–	﹤0.01%	804
2024 Q3	$2.5K	Hold	25	–	–	﹤0.01%	790
2024 Q2	$2.11K	Hold	25	–	–	﹤0.01%	777
2024 Q1	$1.83K	Hold	25	–	–	﹤0.01%	776
2023 Q4	$1.79K	Hold	25	–	–	﹤0.01%	878
2023 Q3	$1.5K	Sell	25 -60	-71%	-$3.95K	﹤0.01%	798
2023 Q2	$6.13K	Buy	85 +22	+35%	+$1.65K	﹤0.01%	602
2023 Q1	$4.63K	Buy	63 +38	+152%	+$2.7K	﹤0.01%	621
2022 Q4	$1.67K	Sell	25 -15	-38%	-$975	﹤0.01%	699
2022 Q3	$2K	Hold	40	–	–	﹤0.01%	659
2022 Q2	$2K	Hold	40	–	–	﹤0.01%	542
2022 Q1	$3K	Buy	+40	New	+$2.9K	﹤0.01%	520

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raleigh Capital Management's LGND Position: Q2 2026 in Review

Raleigh Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 11 shares — an estimated $2.2K sold.

Raleigh Capital Management first reported a position in LGND in Q1 2022 and held it in 13 quarters. The position peaked at $6.13K in Q2 2023. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Raleigh Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Raleigh Capital Management sold 11 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.2K.
Raleigh Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2022 and held it in 13 quarters.
Raleigh Capital Management's Ligand Pharmaceuticals position peaked at $6.13K in Q2 2023.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.